Concentric Analgesics Announces Podium Presentation of Vocacapsaicin Clinical Data at 46th Annual ASRA Meeting
First Scientific Presentation of Positive Data from Phase 2 Total Knee Arthroplasty Study
May 11, 2021
Concentric Analgesics, Inc. today announced the podium presentation of clinical data for vocacapsaicin, its first-in-class non-opioid lead product candidate for the management of postsurgical pain, at the 46th Annual Regional Anesthesiology and Acute Pain Medicine (ASRA) Meeting on May 13, 2021 in Orlando, Florida.
This will be the first scientific presentation of the positive results from the recently completed Phase 2 clinical trial in patients undergoing total knee arthroplasty (“TKA”).
“Vocacapsaicin is the first analgesic that when delivered during surgery reduces postsurgical pain and opioid consumption -- not just for a few days but for a full two weeks following TKA, which is a particularly painful procedure,” said David Leiman, MD, Executive Medical Director of Lotus Clinical Research and a lead investigator in the trial. “I am pleased to be a part of this exciting research program.”
Sam Teichman, MD, Head of Clinical Development at Concentric Analgesics said, “We are delighted that the first scientific presentation of our important new TKA data will be at ASRA. Multi-day postoperative analgesia following TKA remains an important unmet medical need. Vocacapsaicin is Phase 3-ready, and the highly significant Phase 2 results give us confidence that we can bring vocacapsaicin to market expeditiously.”
Details of the presentation are provided below.
Presentation title: Vocacapsaicin Reduces Pain and Opioid Consumption for Two Weeks Following a Single Administration During Total Knee Arthroplasty
Meeting: ASRA Annual Meeting, May 13 – 15, 2021, Orland, Florida (https://www.asra.com/events-education/ra-acute-meeting)
Abstract number: 1734
Venue: Moderated session MP-01a, May 13, 2021, 8:45 AM - 10:15 AM ET
Lead author: Sam Teichman, MD, Head of Clinical Development, Concentric Analgesics
Presenter: David Leiman, MD, Executive Medical Director, Lotus Clinical Research
The poster will be available at: https://epostersonline.com/ASRASPRING21/node/942 and on the Concentric Analgesics website shortly after the presentation.
About Opioid Addiction & Postsurgical Pain
Opioid addiction in the United States has reached epidemic proportions, destroying families, lives and communities throughout the country. According to the Centers for Disease Control and Prevention, approximately 50,000 Americans died from opioid overdoses in 2018 – 30% more than the total number of deaths from automobile accidents. New approaches for preventing this insidious disease are imperative, including in the postsurgical setting, which can be an unsuspecting gateway to prescription pain medicine abuse and beyond. A 2016 US News & World Report revealed that one in 10 patients report becoming addicted or dependent on opioids following surgery. With more than 100 million surgeries performed in the U.S. in 2017, 30 million of which required postsurgical pain management with products that were not over-the-counter (OTC) drugs, the mandate to develop safe and effective non-opioid alternatives is clear.
About Vocacapsaicin (CA-008)
Concentric Analgesics’ lead product candidate for postsurgical pain is a first-in-class prodrug therapeutic that rapidly converts to capsaicin, a potent TRPV1-agonist. Unlike local anesthetics, capsaicin selectively desensitizes pain-conducting nerve fibers without producing sensory numbness or motor weakness. Vocacapsaicin, injected in an aqueous solution during surgery, has the potential to reduce, and in some patients, eliminate the need for opioids in the postsurgical recovery period and provide clinically meaningful pain relief for a week or more. Vocacapsaicin has received both Fast Track Designation (2017) and Breakthrough Therapy Designation (2018) from the FDA.
About Concentric Analgesics
Concentric Analgesics is a clinical-stage, biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics. The company’s portfolio of proprietary products is designed to provide long-lasting, selective pain relief after a single local administration. Vocacapsaicin is the company’s Phase 3-ready lead product candidate for postsurgical pain. Concentric has two additional active programs for multiple indications with significant unmet medical need: osteoarthritis pain and chronic refractory pain. For more information, please visit the company’s website at: www.concentricanalgesics.com.
For More Information:
Frank Bellizzi
Chief Executive Officer
Concentric Analgesics, Inc.
frank@concentricanalgesics.com